2m 2m 2m 2m 2m 2m 2m
BIOXCEL THERPTC (BTAI)
NASDAQ
$1.16-$0.03 (-2.52%)
Price as of Jun 03, 2026 7:38 PM EDT- $36.1MMarket Cap
- -13.14%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
BIOXCEL THERPTC (BTAI)
$1.16-$0.03 (-2.52%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 642,000 -71.67% | 2.3M +64.20% | 1.4M +268.00% | 375,000 N/A | |
Cost of Revenue | 164,000 -92.35% | 2.1M +70.08% | 1.3M +6,200.00% | 20,000 N/A | |
Gross Profit | 478,000 +288.62% | 123,000 +2.50% | 120,000 -66.20% | 355,000 N/A | |
Sales and Marketing Expense | 20.5M -40.58% | 34.5M -58.65% | 83.4M +21.31% | 68.8M N/A | |
Research and Development Expense | -30.3M -0.60% | -30.4M -63.91% | -84.3M -7.58% | -91.2M +73.10% | |
Depreciation and Amortization Expense | 300,000 -2.91% | 309,000 -2.83% | 318,000 -2.75% | 327,000 +10.10% | |
Total Operating Expenses | 51.1M -26.48% | 69.5M -59.86% | 173.2M +8.21% | 160.0M +49.64% | |
Operating Profit | -50.5M -24.96% | -67.2M -60.85% | -171.8M +7.60% | -159.6M +49.29% | |
Interest Income | 1.1M -59.03% | 2.6M -53.94% | 5.6M +123.46% | 2.5M +5,645.45% | |
Interest Expense | -15.3M +4.57% | -14.7M +10.12% | -13.3M +62.11% | -8.2M +20,432.50% | |
Interest Income and Expense and Net | -14.3M +18.29% | -12.1M +57.34% | -7.7M +34.83% | -5.7M -142,225.00% | |
Total Nonoperating Income and Expense | -3.5M -117.44% | 20.2M +5,020.05% | 394,000 +192.27% | -427,000 -1,167.50% | |
Income before Taxes | -50.5M -24.96% | -67.2M -60.85% | -171.8M +7.60% | -159.6M +49.29% | |
Income Taxes | 0 N/A | 0 N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -69.9M +17.28% | -59.6M -66.71% | -179.1M +8.02% | -165.8M +55.01% | |
Net Income from Continuing Operations Applicable to Common | -69.9M +17.28% | -59.6M -66.71% | -179.1M +8.02% | -165.8M +55.01% | |
Basic EPS and Net Income | -5.73 -75.63% | -23.51 +282.28% | -6.15 +3.89% | -5.92 +46.17% | |
Diluted EPS and Net Income | -5.73 -75.63% | -23.51 +282.28% | -6.15 +3.89% | -5.92 +46.17% | |
Basic Weighted Average Shares | 12.2M +381.58% | 2.5M -91.30% | 29.1M +3.98% | 28.0M +6.23% | |
Diluted Weighted Average Shares | 12.2M +381.58% | 2.5M -91.30% | 29.1M +3.98% | 28.0M +6.23% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 28.4M -4.82% | 29.9M -54.23% | 65.2M -66.33% | 193.7M -16.84% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 28.4M -4.82% | 29.9M -54.23% | 65.2M -66.33% | 193.7M -16.84% | |
Total Current Assets | 44.7M +19.50% | 37.4M -48.17% | 72.1M -64.44% | 202.9M -14.33% | |
Accumulated Depreciation | 1.8M +19.97% | 1.5M +25.90% | 1.2M +34.80% | 885,000 +47.01% | |
Property and Plant and Equipment and Net | 175,000 -63.16% | 475,000 -39.41% | 784,000 -27.68% | 1.1M -16.23% | |
Total Long-Term Assets | 0 -100.00% | 87,000 0.00% | 87,000 -90.59% | 925,000 +975.58% | |
Total Assets | 44.9M +17.16% | 38.3M -47.98% | 73.7M -64.20% | 205.9M -14.03% | |
Income Taxes Payable | 32,000 -64.84% | 91,000 -21.55% | 116,000 +41.46% | 82,000 -72.85% | |
Total Short-Term Debt | 24.9M N/A | N/A N/A | 1.4M +231.99% | 422,000 +106.86% | |
Total Current Liabilities | 53.9M +142.55% | 22.2M -18.46% | 27.3M -17.12% | 32.9M +97.38% | |
Total Long-Term Debt | 84.7M -17.41% | 102.5M +1.90% | 100.6M +8.11% | 93.1M N/A | |
Total Long-Term Liabilities | 86.5M -20.83% | 109.2M +6.08% | 102.9M +7.03% | 96.2M +8,604.07% | |
Total Liabilities | 140.4M +6.80% | 131.4M +0.94% | 130.2M +0.88% | 129.1M +626.30% | |
Retained Earnings | -720.1M +10.75% | -650.2M +10.09% | -590.6M +43.51% | -411.5M +67.44% | |
Total Stockholders Equity | -95.5M +2.54% | -93.1M +64.76% | -56.5M -173.60% | 76.8M -65.36% | |
Total Shares Outstanding | 22.3M +619.79% | 3.1M -89.64% | 29.9M +6.33% | 28.1M +0.60% | |
Cash Flow | |||||
Cash from Operating Activities | -57.6M -20.01% | -72.0M -53.53% | -155.0M +14.53% | -135.3M +64.74% | |
Capital Expenditures | 0 -100.00% | 20,000 0.00% | 20,000 -85.61% | 139,000 -68.76% | |
Cash from Investing Activities | 0 +100.00% | -20,000 0.00% | -20,000 -85.61% | -139,000 -68.76% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 56.5M +54.17% | 36.7M +38.22% | 26.5M -72.44% | 96.2M -6.06% | |
Financials Ratio | |||||
Gross Margin | 74.45% +1,271.65% | 5.43% -37.58% | 8.70% -90.81% | 94.67% N/A | |
Operating Margin | -7,859.97% +164.86% | -2,967.56% -76.16% | -12,447.97% -70.76% | -42,572.00% N/A | |
Return on Assets | -167.91% +57.83% | -106.39% -16.95% | -128.10% +72.06% | -74.45% +59.92% | |
Return on Equity | 74.14% -6.95% | 79.67% +104.51% | -1,766.94% +1,490.67% | -111.08% +122.50% | |
Revenue Growth | -71.67% -211.63% | 64.20% -76.04% | 268.00% N/A | N/A N/A | |
Current Ratio | 0.83 -50.73% | 1.68 -36.43% | 2.65 -57.09% | 6.17 -56.60% | |
Cash Ratio | 0.53 -60.76% | 1.34 -43.86% | 2.39 -59.38% | 5.89 -57.87% | |
Debt-to-Equity Ratio | -1.15 N/A | N/A N/A | -1.80 -248.25% | 1.22 N/A | |
Debt-to-Assets Ratio | 2.44 N/A | N/A N/A | 1.38 +204.76% | 0.45 N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow